modelChlortetracycline
Extends from Pharmacolibrary.Drugs.ATC.S.S01AA02.
Information
| name: | Chlortetracycline | |
| ATC code: | S01AA02 | route: | oral |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 0.7 | L |
| clearance: | 30 | ml/min |
| other parameters in model implementation | ||
Chlortetracycline is a broad-spectrum tetracycline antibiotic, formerly used for treating bacterial infections in humans and animals, especially for eye infections (ophthalmic use). Due to resistance and adverse effects, its systemic human use is now rare and it is primarily used topically or in veterinary medicine. It is not currently a first-line approved drug for systemic human use.
Pharmacokinetics
No peer-reviewed human pharmacokinetic study available for chlortetracycline; pharmacokinetic parameters are estimated based on similarities with other tetracyclines and limited historical reports.
References
Zhang, Y, et al., & Yu, M (2022). Florfenicol/Chlortetracycline Effect on Pharmacodynamic Indices for Mutant Selection of . Microbial drug resistance (Larchmont, N.Y.) 28(7) 832–840. DOI:10.1089/mdr.2022.0008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35723674
Cazer, CL, et al., & Gröhn, YT (2018). Expanding behavior pattern sensitivity analysis with model selection and survival analysis. BMC veterinary research 14(1) 355–None. DOI:10.1186/s12917-018-1674-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/30453986
Cazer, CL, et al., & Gröhn, YT (2017). Monte Carlo Simulations Suggest Current Chlortetracycline Drug-Residue Based Withdrawal Periods Would Not Control Antimicrobial Resistance Dissemination from Feedlot to Slaughterhouse. Frontiers in microbiology 8 1753–None. DOI:10.3389/fmicb.2017.01753 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29033901
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)